Medical science and the pharmaceutical industry continue to develop and produce new and more powerful drugs to treat a growing range of diseases for a steadily increasing global population. Healthcare products include a wide variety of vitamins, antibiotics, antipyretics, analgesics, antidepressants and many more pharmaceutical products for both human and livestock consumption. As a result, the world's pharmaceutical industry has become one of the fastest growing (and profitable) business sectors in the twenty-first century. In 2010, China alone was reported to have approximately 2500 registered pharmaceutical manufacturers, an increase of 7.5% year-on-year, resulting in a corresponding increase in sales by 10.9%. In the same year China became the largest exporter of active pharmaceutical ingredients (APIs), numbering more than 1100. Going forward, API production growth rates are expected to be higher in the developing countries including China, India and Brazil in the near future in comparison with those of the United States, Germany and Italy. Many of these pharmaceutical building blocks are exported to drug manufacturers in North America and Europe.
Not unexpectedly the pharmaceutical industry produces substantial volumes of waste, either directly or indirectly. These waste materials are generated both in the manufacturing process and by consumers who typically discard unused or outdated products. Pharmaceuticals appear as waste in production and distribution, as non-used medicine and in excreta from animals and humans. Post-consumer sources of pharmaceutical waste materials can be significant because they contain near-full strength concentrations of antibiotics, antiparasitics, hormones, analgesics, psychotropic medicines and many more natural and synthetic chemicals into the environment. Both manufacturing and post-consumer sources can lead to environmental degradation, particularly because many of the compounds in the waste streams are highly persistent and non-degradable in nature, and may be bio-accumulative. Thus, pharmaceuticals, like many other products, can be considered as both a major benefit to society and a public health liability if waste materials are not properly managed. In fact, pharmaceutical waste materials have been classified as highly dangerous waste by the World Health Organization (WHO). The WHO's list of pharmaceutical waste covers expired, unused, spilt and contaminated pharmaceutical products, drugs and vaccines, discarded items used in the handling of pharmaceuticals, and all drugs and equipment used for the mixing and administration of cytotoxic or genotoxic drugs.
The dominance of synthetic APIs in global commerce creates a pharmaceutical waste management challenge. In particular, the inherent properties of this type of waste resist destruction by traditional biological processes used at most wastewater treatment plants. Therefore, residual solids containing this type of waste will persist in the environment, perhaps with only minimal degradation. The intensity of the impacts due to the release of pharmaceutical waste is uncertain since there has been little research on this subject. In addition, scientists and engineers know little about environmental and public health impacts associated with discharge of pharmaceutical waste regarding key issues such as the metabolic pathways of the affected organisms and the aggregate toxicity of fusions of substances. Yet, some eco-toxicity data has revealed that the presence of these components does pose threats to the environment. In Patancheru, India, for example, approximately 45 kg of the antibiotic ciprofloxacin has been discharged daily, an equivalent of the total consumption of this substance in Sweden over an average five-day period. In 2009, it was reported that surface waters in the USA, which are the source of drinking water for many cities, was contaminated with nothing less than 0.12 million tonnes of pharmaceuticals.
Among the most comprehensively documented impacts from pharmaceuticals in the environment are the potent effects of ethinyl estradiol (EE2) on some species of male fish and the mass poisoning of vultures by diclofenac. EE2 is a major compound in the estrogenic chemical used for oral contraceptives while diclofenac, a veterinary pharmaceutical, is commonly administered to sick livestock. These disturbing effects on wildlife can potentially disrupt the equilibrium within the food web. Thus, necessary actions need to be taken to monitor the environmental vulnerability towards these alien compounds.
The existing guideline for safe pharmaceutical waste disposal was developed by the WHO in 1999. However, the guideline does not address the options for a holistic approach to source reduction or management of pharmaceutical wastes. The main weakness of this guideline is the absence of advice on how government agencies might regulate waste generation and/or disposal practices by pharmaceutical manufacturers. Although more focus was directed to the advancement in the pharmaceutical sector, the failure to address the impact of pharmaceuticals in the environment is an oversight that should be corrected when the guidelines are next updated. Developments in 2010 suggest that conditions will improve. For instance, the European Environmental Agency (EEA) published its Technical Report (No 1/2010 Pharmaceuticals in the Environment) on the subject reflecting results of the EEA workshop on pharmaceuticals in the environment. Various strategies are set forth to protect the environment from the threats posed by improper or incomplete disposal of pharmaceuticals. However similar progress towards development of regulations is not found in developing countries.
Life-cycle assessment has been identified as a means to monitor the real cost of managing pharmaceutical wastes, from 'cradle to grave'. The objective is to determine and publicize the full costs associated with the development, manufacture, and consumption of pharmaceuticals, including the management of wastes so that those in industry and government responsible for environmental protection can develop systemic waste management solutions instead of piecemeal and thus inefficient band aids. Greener pharmacy is also introduced with the aim of encouraging pharmaceutical companies to incorporate environmental impacts analyses in their R&D programmes. It is also identified as a strategy where the concept of 'benign by design' is considered to increase incentives in developing 'harmless' pharmaceuticals. 'Take-back' schemes may also have a role; these would be established to make it convenient for consumers to separately and safely dispose of used or expired pharmaceuticals, similar to longstanding community hazardous waste collection centres or events in some developed countries. Proper disposal could be further encouraged by incorporating consumer-friendly labelling and physician instructions on products. In addition, comprehensive information should be made available to guide policy makers on the management of pharmaceuticals. In this manner environmental risk assessment could be carried out hand-in-hand with risk-benefit analysis to justify the evaluation of risks from the pharmaceuticals. Enhanced monitoring strategies are also crucial in order to ensure that the substances' fate and impacts are properly tracked and recorded. This will enable both manufacturers and regulators to regularly measure their progress toward reducing the presence of pharmaceuticals in the environment.
The noble benefits of pharmaceuticals as a means of enhancing human health have generally overshadowed the adverse environmental impacts of improper or incomplete disposal of the associated residues. Ignorance of the longterm effects of these substances in the ecosystem has resulted in reported increases in infertility, genital deformities, and hormone-triggered cancer, and an upsurge in neurological disorders, all signs that the management of pharmaceuticals in the environment is a serious challenge. Scientists who develop life-saving or life-extending pharmaceuticals are properly hailed as heroes. It is now up to the pharmaceutical industry and government regulatory agencies to become heroes in their own right by devising and implementing methods and systems to minimize if not eliminate the unintended negative environmental and public health consequences associated with pharmaceutical production and use.
